Speaker
Description
Albumin-based nanocarrier systems are increasingly gaining attention in cancer treatment due to their biocompatibility, long circulation times, and tumour-specific targeting capabilities. Albumin nanocarriers can be naturally taken up into tumour tissue via gp60 and SPARC-mediated mechanisms. Three-dimensional tumour models and in vivo studies demonstrate that albumin nanocarriers distribute within tumour tissue like a natural biomaterial, and conjugation with RGD, folate, transferrin, and aptamers significantly enhances cellular uptake. Furthermore, albumin nanocarriers enable tumour-specific drug delivery and significantly reduce systemic toxicity by exploiting their sensitivity to the tumour microenvironment (pH, ROS, and enzyme-sensitive nanocarriers). These controlled release strategies also offer advantages in overcoming multidrug resistance (MDR). Furthermore, albumin is highly successful in drug delivery in 3D tumour models and, when combined with imaging agents, becomes a multi-purpose carrier. All these features make albumin-based nanocarriers a strong clinical candidate for targeted, controlled drug delivery with reduced side effects and safe drug delivery systems.
